Resources
Application Form B for Conditions other than Group 1 – Inborn Errors of Metabolism
Form
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism (other than DHPR, hyperphenylalaninemia and PKU).
Application to register as an Approved Metabolic Specialist – Inborn Errors of Metabolism
Form
Specialist doctors can use this form to apply for registration as an approved metabolic specialist under the Inborn Errors of Metabolism (IEM) program.
Application Form C – Change of details – Inborn Errors of Metabolism
Form
Individuals registered with the Inborn Errors of Metabolism program can use this form to change their personal information.
Application Form A for Conditions Group 1 – Inborn Errors of Metabolism
Form
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism — DHPR, hyperphenylalaninemia and PKU conditions only. For other conditions, use Application Form B.
National Strategy for Health Practitioner Pain Management Education
Strategy or framework
The National Pain Management Health Practitioner Education Strategy was launched on 6 October 2023. The strategy was developed by the Faculty of Pain Medicine (FPM), Australian and New Zealand College of Anaesthetists (ANZCA) with funding from the Australian Government.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 20 October 2023
Agenda
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 16th meeting on 20 October 2023.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 23 August 2023
Meeting minutes
This communique provides a summary of the advisory committee's meeting on 23 August 2023.
National Site of Recognition Steering Committee communique – 10 July 2023
Meeting minutes
Details of the fifth meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 10 July 2023.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 21 July 2023
Meeting minutes
This communique provides a summary of the advisory committee's meeting on 21 July 2023.
Chronic health plans – Easy Read
Fact sheet
This fact sheet tells you about health care plans for chronic health problems. Chronic means something lasts a long time. Chronic health problems last a long time. You can download the fact sheet in PDF to read online or print.
Referral form for chronic disease allied health services under Medicare
Form
GPs can use this referral form to refer a patient with a chronic medical condition and complex care needs for Medicare rebateable allied health services under the Chronic Disease Management (CDM) Medicare items.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 4 July 2023
Meeting minutes
This communique provides a summary of the advisory committee's meeting on 4 July 2023.
Newborn bloodspot screening – Public consultation infographic
Fact sheet
This publication outlines the key findings from our public consultation on the expansion of newborn bloodspot screening programs.
Public consultation on the expansion of newborn bloodspot screening
Report
This report gives an overview of the public consultation process that we undertook for the expansion of newborn bloodspot screening programs.
National Fetal Alcohol Spectrum Disorder (FASD) Strategic Action Plan 2018-2028 – Three-year implementation review
Report
This report shares review findings of the National Fetal Alcohol Spectrum Disorder (FASD) Strategic Action Plan 2018-2028 implementation. The review’s aim is to inform the Australian Government if the plan is on-track to achieving its goals.
Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement
Report
This document states the outcome of Sanofi-Aventis Australia's application to include eliglustat on the Life Saving Drugs Program.
Life Saving Drugs Program – Change of treating physician form
Form
Use this form to help transition a patient’s care to a new physician, where there are no other changes to their treatment or eligibility for the Life Saving Drugs Program (LSDP).
Life Saving Drugs Program – Fact sheet for treating physicians
Fact sheet
This fact sheet gives answers to common questions about the role of treating physicians in prescribing Life Saving Drugs Program (LSDP) medicines.
Life Saving Drugs Program – Fact sheet for patients
Fact sheet
Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Sebelipase alfa (Kanuma®) outcome statement
Report
Summary of the consideration of the application from Alexion Australia for the inclusion of sebelipase alfa (Kanuma®) on the LSDP for the treatment of infantile onset lysosomal acid lipase deficiency (LAL-D).
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 26 May 2023
Agenda
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 15th meeting on 26 May 2023.
National Site of Recognition Steering Committee communique – 2 March 2023
Meeting minutes
Details of the forth meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 2 March 2023.
Acute rheumatic fever and rheumatic heart disease – CDNA National Guidelines for Public Health Units
Guideline
These guidelines for Public Health Units provide nationally consistent guidance on how to respond to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). They are part of a Series of National Guidelines (SoNGs) published by the Communicable Diseases Network Australia (CDNA).
Life Saving Drugs Program – PNH – Review summary and Expert Panel recommendations
Procedure
This PNH review considered eculizumab. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – PNH – Review summary and Expert Panel recommendations for consumers
Procedure
This PNH review considered eculizumab. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Date last updated:
Tags: